Showing 111-120 of 129 results for "".
- Sun Safety Day at Wrigley a Success for Sun Heroeshttps://practicaldermatology.com/news/sun-safety-day-at-wrigley-a-success-for-sun-heroes/2461261/As an extension of the Sun Heroes initiative, CeraVe's Sun Safety Day at Wrigley Field in partnership with Amy Brodsky, MD brought sun protection education to attendees as the Chicago Cubs hosted the Atlanta Braves. Dr. Brodsky founded
- Calling All Dermatologists: The Sun Heroes Initiative Wants You to Become a Herohttps://practicaldermatology.com/news/calling-all-dermatologists-the-sun-heroes-initiative-wants-you-to-help-bring-sun-safety-programs-to-elementary-schools/2461232/CeraVe and L'Oreal Dermatological Beauty brand La Roche-Posay are teaming up with dermatologist Amy Brodsky, MD to bring sun safety programs to elementary schools around the country. Sun Heroes is an educational program that equips healthcare professionals with
- Leadership Changes Take Place at SkinCeuticalshttps://practicaldermatology.com/news/leadership-changes-at-skinceuticals/2461069/Stephanie Kramer is now SkinCeutical’s Global General Manager, and Amy Sloan is the Head of SkinCeuticals U.S, the company reports Sloan brings 15 years of global and U.S. beauty industry experience - 10 of those years with SkinCeuticals - to the role of Head o
- Neauvia’s Introduces Zaffiro, A Two-Part Solution to Skin Rejuvenationhttps://practicaldermatology.com/news/neuvias-introduces-zaffiro-a-two-part-solution-to-skin-rejuvenation/2460305/Neauvia introduced Zaffiro to the media at an event held in New York City’s Hudson Yards, featuring New York City dermatologist Amy Lewis, MD Launched in the US in late 2019, the Zaffiro device is a dual facial rejuve
- Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositishttps://practicaldermatology.com/news/investigational-cannabinoid-receptor-agonist-proves-safe-and-effective-in-amyopathic-dermatomyositis/2461357/Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, a new study in the Journal of Investigative Dermatology suggests. This phase 2 trial, the
- Amytrx Therapeutics Raises $18M for New AD Treatmenthttps://practicaldermatology.com/news/amytrx-therapeutics-raises-18m-for-new-ad-treatment/2461211/Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research investigating AMTX-100, a new cell- penetrating immune system modulating peptide therapeutic for topical skin applications, specifically in atopic derma
- Amytrx Therapeutics Comes Out of the Gate Strong with Lead Program AMTX-100, Clinical Development Planshttps://practicaldermatology.com/news/amytrx-therapeutics-comes-out-of-the-gate-strong-with-lead-program-amtx-100-clinical-development-plans/2460531/Amytrx Therapeutics, Inc. is on the move. Founded in 2014, Nashville-based Amytrx is developing novel therapies for inflammatory diseases with lead program AMTX-100 currently in clinical development for dermatologic indications. AMTX-100 is a new anti-inflammatory therape
- Open Enrollment Underway for Phase 2b Trial of Topical AMTX-100 CF3 in ADhttps://practicaldermatology.com/news/open-enrollment-underway-for-phase-2b-trial-of-topical-amtx-100-cf3-in-ad/2461827/Amytrx Therapeutics is enrolling mild to moderate atopic dermatitis patients for its Phase 2b clinical trial of a topical formulation of AMTX-100 CF3. Eligible adults interested in participating or learning more about the trial are encouraged to visit the
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t
- Amy Klinkhttps://practicaldermatology.com/profiles/amy-klink/OE6nYP/